Trial Profile
Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Oct 2021
Price :
$35
*
At a glance
- Drugs Amisulpride (Primary)
- Indications Postoperative nausea and vomiting
- Focus Registrational; Therapeutic Use
- Sponsors Acacia Pharma
- 29 Sep 2021 According to a Acacia Pharma media release, based data from four positive Phase 3 studies, the company has submitted a Marketing Authorization Application (MAA) for BARHEMSYS (amisulpride injection) to prevent and treat postoperative nausea & vomiting (PONV). The MAA has been validated and is now under formal review in major European markets. The review process is expected to be completed by Q3/2022.
- 07 Oct 2014 Top-line results reported in an Acacia media release.
- 07 Oct 2014 Primary endpoint (significantly lower proportion of amisulpride vs placebo recipients with no PONV in postoperative 24h) has been met, according to an Acacia media release.